item management s discussion and analysis of financial condition and results of operations the following discussion of operations and financial condition of lifecell should be read in conjunction with the financial statements and notes thereto included elsewhere in this annual report on form k 
special note certain statements set forth below constitute forward looking statements within the meaning of section a of the securities act and section e of the exchange act 
see business special note regarding forward looking statements 
general and background lifecell was organized in and  since its inception  has been financed through the public and private sale of equity securities  through product sales  through a corporate alliance with medtronic and through the receipt of government grants and contracts 
lifecell began the sale of alloderm grafts as a dermal replacement in the grafting of third degree burns in december and commenced commercial activities in lifecell commenced the sale of alloderm for periodontal surgery in september and for reconstructive plastic surgery in november to date  proceeds from the sale of alloderm products have not been sufficient to fund in full the company s operating activities 
results of operations year ended december  and the net loss for the year ended december   increased to approximately million compared to approximately million for the same period of the increase was principally attributable to costs associated with expanding the sales of alloderm  including the development of sales and marketing programs  recruitment and retention of staff and the related infrastructure necessary to support such activities 
total revenues for the year ended december   increased to approximately million compared to approximately million for the same period of approximately million of such increase was attributable to increases in sales of products  which were the result of expanded sales and marketing activities and increased distribution activities during the period 
the remaining  increase in revenues was the result of increased research activities under funding arrangements  amounts recognized as revenues under such cost reimbursement arrangements are for the associated expenses incurred during the periods 
cost of goods sold for the year ended december   was approximately million  resulting in a gross margin of approximately 
the gross margin for the year ended december   was approximately 
the increase in gross margin was principally attributable to the implementation of certain production efficiencies  the allocation of fixed costs to higher volumes of products  an increase in sales of certain higher margin alloderm products and an increase in the price of certain alloderm products in research and development expenses for the year ended december   increased to approximately million compared to approximately million for of such increase  approximately  was attributable to increased activities related to research funded by others 
such activities increased in as a result of the receipt during of three contracts with government agencies to fund research and development activities 
the remaining  increase in research and development expense was attributable to increased production of products for clinical and research activities as well as higher allocations of resources to certain proprietary research and development programs 
general and administrative expenses for the year ended december   increased to approximately million compared to approximately million for such increase was principally attributable to legal fees accrued for the defense of the patent infringement lawsuit  increased staff levels  recruiting fees and other professional fees related to the company s expansion of the infrastructure to support its increased sales activities 
selling and marketing expenses increased to approximately million for the year ended december   compared to approximately million for the increase was primarily attributable to increased promotional activities as well as the addition of sales personnel related to alloderm marketing 
interest income and other  net increased to approximately  for the year ended december   compared to approximately  for the increase was principally attributable to higher funds available for investment during the current period as a result of the sale of series b preferred stock in november and the proceeds received from the public offering of common stock in december years ended december  and total revenues for increased to approximately million compared to approximately million for as a result of increased marketing activities  expansion of distribution channels and expanded uses of the company s alloderm product  product sales for the year increased to million from  for revenue from research funded by others decreased to  from million for  principally as a result of lower revenues under the medtronic arrangement  offset by higher revenues under government grants 
the company received two new grants in for its thrombosol and composite skin programs 
total costs and expenses for increased to million  compared to million for the same period of the prior year principally as a result of expanded sales and marketing activities for the company s products and costs related to such expanded activities 
cost of goods sold for increased to million compared to  in the same period of this increase was due to an increase in product sales and the shift from the development of alloderm to processing  consistent with taking a product to market 
total research and development expenses decreased to million in from million in as a result of lower expenditures under its research funded by others as well as the shift in the company s focus from the development of alloderm to processing 
general and administrative expense increased to million in  from million in principally as a result of expanded administrative activities as the company increased its product sales and marketing activities as well as certain administrative expenses recognized in conjunction with its financing activities and non cash charges related to the reissuance of certain stock options 
selling and marketing expenses increased to million for from million in primarily due to the addition of sales personnel and promotional activities related to alloderm marketing and expanded distribution activities 
interest income and other  net decreased to  for compared to  for as a result of the decrease in funds available for investment prior to the receipt of funds from an equity financing in late  as well as lower interest rates in liquidity and capital resources since its inception  lifecell s principal sources of funds have been equity offerings  product sales  external funding of research activities and interest on investments 
lifecell has historically funded research and development activities for products other than alloderm primarily with external funds from its corporate alliance with medtronic and government grants 
in april  lifecell was awarded a  contract from the united states navy related to the development of thrombosol 
in august  lifecell was awarded a two year  national science foundation grant related to its keratinocytes program 
in december  lifecell was awarded a two year contract of approximately million from the united states army to support the development of vascular graft and other products 
in  lifecell entered into an agreement with medtronic pursuant to which medtronic paid lifecell a license fee of million and agreed  subject to certain rights to terminate at medtronic s discretion  to fund certain costs of the research and development of lifecell s proprietary tissue processing technology in the field of heart valves 
through december   lifecell has recognized approximately million in revenues for development funding  excluding the initial license fee  for this program 
in november  lifecell received net proceeds of approximately million pursuant to the private sale of series b preferred stock and warrants exercisable for the purchase of common stock 
in december  lifecell received net proceeds of approximately million pursuant to a public offering of million shares of common stock 
in november  integra and mit filed a lawsuit against the company alleging that the use of alloderm infringes the integra patents 
although the company denies the allegations of patent infringement  there can be no assurance as to the outcome of this matter or as to the effect  if any  that the outcome may have on the company s business  financial condition or results of operations 
see business risk factors patent infringement lawsuit and business risk factors dependence on patents and proprietary rights 
in december  lifecell filed a lawsuit in texas state court against integra lifesciences corporation and mit alleging that they tortiously interfered with certain of lifecell s business relationships  including relationships with investors and potential investors in lifecell s recent public offering 
there can be no assurance as to the outcome of this matter or as to the effect  if any  that the outcome may have on the company s business  financial condition or results of operations 
see legal proceedings 
lifecell expects to incur substantial expenses in connection with its efforts to expand sales and marketing of alloderm  develop expanded uses for alloderm  conduct the company s product development programs including costs of clinical studies  prepare and make any required regulatory filings  introduce products  participate in technical seminars and support ongoing administrative and research and development activities and may incur substantial expenses in connection with defending the lawsuit relating to the integra patents and pursuing its tortious interference claims against integra and mit 
the company currently intends to fund these activities from its existing cash resources  sales of products and research and development funding received from others 
while the company believes that its existing available funds will be sufficient to meet its present operating and capital requirements through at least  there can be no assurance that such sources of funds will be sufficient to meet these future expenses 
if adequate funds are not available  the company expects it will be required to delay  scale back or eliminate one or more of its product development programs 
the company s need for additional financing will be principally dependent on the degree of market acceptance achieved by the company s products and the extent to which the company can achieve substantial growth in product sales during and  as well as the extent to which the company may decide to expand its product development efforts 
there can be no assurance that the company will be able to obtain any such additional financing on acceptable terms  if at all 
see business risk factors no assurance of additional necessary capital 
lifecell has had losses since its inception and therefore has not been subject to federal income taxes 
as of december   lifecell had net operating loss nol and research and development tax credit carryforwards for income tax purposes of approximately million and  respectively  available to reduce future income tax and tax liabilities 
federal tax laws provide for a limitation on the use of nol and tax credit carryforwards following certain ownership changes that could limit lifecell s ability to use its nol and tax credit carryforwards 
the sale of common stock in the recent public offering resulted in an ownership change for federal income tax purposes 
the company estimates that the amount of nol carryforwards and the credits available to offset taxable income subsequent to the offering will be approximately million per year on a cumulative basis 
accordingly  if lifecell generates taxable income in any year in excess of its then cumulative limitation  the company may be required to pay federal income taxes even though it has unexpired nol carryforwards 
item a 
quantitative and qualitative disclosure about market risk none 

